UBS’ new price target for General Motors still implies that shares could gain 11% from their current valuations.
Related Posts
Biogen tops estimates, raises profit guidance as Alzheimer’s drug Leqembi gains traction
Leqembi, along with rare disease and depression treatments, helped offset a year-over-year decline in revenue for the company’s multiple sclerosis products.
‘A necessary evil’: Fund managers are changing tack on defense stocks
Fund managers are screening defense firms to make them more palatable to ESG-minded investors as the sector grows in the face of geopolitical tensions.
South Korean stocks rocked in U.S. trading as country plunges into political chaos
The iShares MSCI South Korea ETF, which tracks more than 90 large and mid-sized companies in South Korea, tumbled 6% to hit a 52-week low.